- Home
- Products
CAPRELSA (Vandetnib)
CAPRELSA (Vandetnib)
- Medicine Name: CAPRELSA
- Generic Name: Vandetanib
- Dosage Form & Strength: Tablets available in 100 mg and 300 mg
- Form: Oral Tablet
- Manufactured By:AstraZeneca Pharmaceuticals LP
- FDA Approval Date:Yes (April 6, 2011)
CAPRELSA (Vandetanib) is a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.
Recommended Dosage:
- 300 mg taken orally once daily
- Can be taken with or without food
- Tablets must not be crushed
- If needed, tablets may be dispersed in 2 ounces of water and consumed immediately or administered via nasogastric/gastrostomy tubes.
Do not take a missed dose within 12 hours of the next scheduled dose.
Click here to download full prescribing information.
Baseline Monitoring: ECG, potassium, magnesium, calcium, and TSH should be assessed at treatment start, at 2–4 weeks, 8–12 weeks, and every 3 months
QT Prolongation: Avoid use with drugs that prolong QT interval
Severe Skin Reactions: Includes Stevens-Johnson syndrome. Therapy should be discontinued in severe cases
Photosensitivity: Can persist up to 4 months post-treatment
Interstitial Lung Disease (ILD): May be fatal. Discontinue if ILD is confirmed
Cerebrovascular Events: Discontinue if severe ischemic stroke occurs
Heart Failure: Monitor closely; discontinue if non-reversible
Severe Hemorrhage: Contraindicated in patients with recent hemoptysis
Thyroid Function: Monitor TSH levels and adjust thyroid replacement therapy if required
Hypertension: May require dose interruption or discontinuation
Pregnancy Warning: Vandetanib may cause fetal harm. Avoid during pregnancy
Documents required for import to India:
- Valid prescription from a qualified physician
- Diagnostic reports supporting the indication
- Government-issued photo ID of the patient
- Import permit, if required under Indian regulations
CAPRELSA Availability:
Not approved for sale in India, but available for Named Patient Use with proper documentation. Delivery can be arranged across major cities in India including Mumbai, Delhi, Bangalore, Chennai, Hyderabad, Ahmedabad, Pune, and others.
Global Rare Meds facilitates procurement of CAPRELSA (Vandetanib) through verified global partners.
- Dispensation from our fulfillment center in Ambernath, Thane District
- Orders are handled by licensed pharmacists
- Adheres to strict cold-chain and handling procedures
- Delivery available across India and select international destinations, subject to import regulations
We ensure full compliance, quality assurance, and secure delivery processes.
What is the generic name of CAPRELSA?
Vandetanib
Is CAPRELSA approved by the FDA?
Yes, CAPRELSA was approved by the FDA on April 6, 2011.
What is CAPRELSA used for?
It is used to treat progressive or symptomatic medullary thyroid cancer that cannot be surgically removed or has metastasized.
What are the dosage forms of CAPRELSA?
CAPRELSA is available in 100 mg and 300 mg oral tablets.
What are the most common side effects?
Rash, diarrhea, nausea, acne, headache, high blood pressure, fatigue, abdominal pain, upper respiratory infections.
How is CAPRELSA stored?
Store at 25°C (77°F); excursions between 15°C and 30°C are permitted. Do not crush tablets.
Can I buy CAPRELSA in India?
Yes, under Named Patient Import, subject to documentation.
Is CAPRELSA available in generic or biosimilar form?
No, there are no approved generics or biosimilars for Vandetanib.
How do I get CAPRELSA pricing information?
Contact Global Rare Meds:
Phone: +91-99675 15602
WhatsApp: +91-99675 15602
Email: info@globalraremeds.com
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
